The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
The term interstitial lung disease (ILD) includes an enormous amount of parenchymal pulmonary disorders (>200). The appropriate and strict categorization of the underlying process was always considered pivotal for the management, as well as the prediction of outcomes. The vast majority of the ILDs are categorized in some connective tissue disease associated ILD (such as Rheumatoid arthritis, Scleroderma, Sjogren’s). The most well studied and most devastating ILD is Idiopathic Pulmonary Fibrosis (IPF), with other well studied ILDs being chronic hypersensitivity pneumonitis (CHP), Non-specific Interstitial pneumonia (NSIP) and Sarcoidosis-ILD. When the accurate diagnosis cannot be pinpointed the patient may be “classified” as Unclassifiable. To highlight the unknowns around unclassifiable ILD and to allow further research into the condition, a research group established a new diagnostic entity termed interstitial pneumonia with autoimmune features (IPAF). All these different classifications has led to much clinical and translational research, but in fact, there are actually no advances in the pharmacological treatment of ILD patients, other than IPF, compared to 10 or 20 years ago, thus highlighting the major unmet need. ILD dominates the morbidity and mortality in all these individual categories and while in some cases the disease can be self-limited or controlled by immunosuppression and antigen removal in the case of CHP, in other cases the fibrosis can take its own course, become self-sustained, progressive and fatal. Until now, though these patients were not entitled to receive any additional therapy and the novel antifibrotics, Nintedanib and Pirfenidone, were only indicated for IPF. Pirfenidone aimed to evaluate its efficacy at treating patients with unclassifiable disease, including patients with IPAF. In a Randomized Placebo Controlled, phase 2 clinical trial the authors aimed to establish a new and innovative endpoint for ILD trials, using home-based FVC measurement as the primary endpoint. Unfortunately, there were obvious technical difficulties and the endpoint of the trial was not met. However, the exploratory data, including the classical endpoint in IPF trials (rate of FVC decline) were overwhelming. At 24 weeks, the Pirfenidone treated group showed almost stable FVC, as the decline was only 17.8 mL compared 113.0 mL in the placebo group. The study had several other limitations, regarding the diagnosis of Unclassifiable and the absence of central CT review. Collectively, the trial was a negative study with many limitations and the secondary endpoints, although positive, should be interpreted with caution. Nevertheless, the data are encouraging for patients with unclassifiable ILDs that no approved therapy exists to date.
/* NOTE - this is usually hard-coded in the wysiwyg for existing imported content */ ?>
Share this article
Interstitial lung diseases
Respiratory digests
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.